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Binding of HSV to cells is not sufficient to mediate pene-Northwestern University Medical School
tration. Certain cell types, such as swine testis (ST) orDepartment of Microbiology-Immunology
Chinese hamster ovary (CHO) cells, can bind virus effi-303 East Chicago Avenue
ciently but restrict viral entry (Shieh et al., 1992; Subra-Chicago, Illinois 60611
manian et al., 1994). Susceptible cells can be made
resistant to HSV entry while retaining ability to bind virus
by transfection with plasmids expressing HSV gD (Cam-Summary
padelli-Fiume et al., 1988; Johnson and Spear, 1989).
These observations suggest that cell-associated gDWe identified and cloned a cellular mediator of herpes
may sequester or down-regulate a cellular protein re-simplex virus (HSV) entry. Hamster and swine cells
quired for HSV entry and that ST and CHO-K1 cells failresistant to viral entry became susceptible upon ex-
to express such a mediator of HSV entry.pression of a human cDNA encoding this protein, des-
By screening a human cDNA expression library forignated HVEM (for herpesvirus entry mediator). HVEM
genes that could mediate HSV-1 entry into CHO-K1was shown to mediate the entry of several wild-type
cells, we identified a previously undescribed memberHSV strains of both serotypes. Anti–HVEM antibodies
of the tumor necrosis factor/nerve growth factor (TNF/and a soluble hybrid protein containing the HVEM ec-
NGF) receptor family, designated HVEM. This receptortodomain inhibited HVEM–dependent infection but not
mediated efficient entry of HSV-1 strains into CHO-K1virus binding to cells. Mutations in the HSV envelope
cells and ST cells and also enhanced the entry of anglycoproteingDsignificantly reduced HVEM–mediated
HSV-2 strain. HVEM was active inmediating HSV-1 entryentry. The contribution of HVEM to HSV entry into
into human T lymphoblasts.human cells was demonstrable in activated T cells.
HVEM, the first identified mediator of HSV entry, is a
Resultsnew member of the TNF/NGF receptor family.
Cloning a Mediator of HSV-1 Entry
Introduction The CHO-K1 cell line is particularly resistant to entry of
HSV-1 strain KOS (Shieh et al., 1992), abbreviated here
Herpes simplex viruses (HSV) are human members of KOS. A b-galactosidase–expressing version of this
the neurotropic subgroup (alphaherpesviruses) of the strain, HSV-1(KOS)gL86 abbreviated here KOS-gL86,
herpesvirus family. Infections with HSV type 1 (HSV-1) was used to monitor viral entry. Production of b-galac-
and HSV type 2 (HSV-2) are highly prevalent. The usual tosidase from the input viral genome signals that virus
manifestations of disease (reviewed by Corey and has entered the cell, released its genome to the nucleus,
Spear, 1988) are mucocutaneous lesions of the mouth, and activated the consititutive promoter driving b-galac-
face, eyes, or genitalia. Both HSV-1 and HSV-2 establish tosidase expression. Figure 1A shows that HeLa (hu-
latent infections in neurons of peripheral ganglia and man) cells were susceptible to infection by this virus,
may reactivate to cause recurrent lesions. Rarely, the whereas CHO-K1 cells were highly resistant. Concentra-
virus spreads to the central nervous system to cause tions of input virus sufficient to infect 100% of HeLa
meningitis or encephalitis. cells left the CHO-K1 cells totally uninfected (Figure 1B).
Viral infection in the natural host usually remains local- The strategy to isolate a human cDNA that enhanced
ized to cells of the epidermis and peripheral nervous HSV-1 entry into CHO-K1 cells combined transient ex-
system, except in newborn infants, who are more prone pression of cDNAs with KOS-gL86 challenge. Plasmid
to disseminated infection. Differentiatedcell types prob- DNAs prepared from pools of a HeLa cell cDNA library
ably vary in their susceptibility to HSV entry. However, were transfected into CHO-K1 cells. The cells were ex-
cultured cells of various types from many animal species posed to KOS-gL86 and then X-gal to identify infected
are susceptible to HSV infection, indicating that cell re- cells. A pool containing a positive cDNA was subdivided
ceptors for viral entry may be highly conserved or are by an iterative process to identify individual plasmid
multiple innumber and are usually expressed ondividing clones that had the desired phenotype.
cells. A set of two plasmid clones (pBEC580 and pBEC748)
The binding and penetration phases of HSV entry into that rendered transfected CHO-K1 cells susceptible to
cells can be experimentally dissociated. Binding of KOS-gL86 entry (Figures 1B and 1C) were isolated. Nu-
HSV-1 or HSV-2 to cells is mediated by interaction of cleotide sequencing of the cDNA insert (the same for
viral envelope glycoproteins (gB or gC or both) with both plasmids) revealed a 1698 bp cDNA encoding an
glycosaminoglycan chains (GAGs) of cell surface pro- open reading frame of 283 amino acids (Figure 2). The
teoglycans (reviewed by Spear, 1993). Penetration is by protein product, designated HVEM, has characteristics
pH-independent fusion of the virion envelope with the of a type I membrane glycoprotein with an N-terminal
cell plasma membrane or an early endosome (Wittels signal peptide, two potential sites for addition of
and Spear, 1991). Viral glycoproteins required for pene- N-linked glycans, and a probable membrane-spanning
domain.tration include gB, gD, and gH–gL hetero-oligomers
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DNA fragment from three different human cell lines
(HT1080 not shown) and to a single DNA fragment of
different size from monkey cells (Figure 3B). The full-
length EcoRI probe lacked sites for the restriction endo-
nuclease used to digest the cell DNAs (BamHI) yet hy-
bridized to additional bands in human and monkey DNA
samples (Figure 3C). Thus, it is likely that HVEM is en-
coded by a single-copy human gene with multiple exons
and that nonhuman primates have a related gene.
Expression of HVEM
Labeled probes prepared from HVEM cDNA were hy-
bridized to a Northern blot of polyadenylated RNAs ex-
tracted from several human tissues. HVEM–related
RNAs were detected in most samples tested, with high-
est levels in lung, liver, and kidney and least in brain
(Figure 3E). The RNAs were heterogeneous in size. One
species of about 2 kb was similar in size to the HVEM
cDNA. The presence of larger species (4–5 kb) suggests
that transcription of the gene for HVEM may result in
multiple mRNAs.
We produced hybrid and epitope-tagged versions of
HVEM to verify expression of the protein and to isolate
material for immunization and detection of antibodies.
HVEM:Fc, comprising the three-and-a-half cysteine-rich
repeats of the ectodomain (see Figure 2) fused in-frame
to the Fc region of rabbit IgG heavy chain, was secreted
from transfected cells as a glycoprotein (about 50–65
Figure 1. Entry of HSV-1 into HeLa Cells, CHO-K1 Cells, and kDa). Changes in size after treatment of HVEM:Fc with
Transfected CHO-K1 Cells glycosidases were consistent with presence of O-linked
(A) CHO-K1 cells or HeLa cells were exposed to KOS-gL86 at the and complex N-linked carbohydrate chains (Figure 4A).
doses indicated. After the addition of virus (6 hr), infection was The glycosylation and secretion of HVEM:Fc suggests
quantitated by monitoring the activity of b-galactosidase expressed that the hydrophobic region between amino acids 23
from the input viral genome. In this and other figures, each point
and 38 serves as a signal sequence even though it doesrepresents the mean of triplicate determinations. The individual val-
not strictly adhere to rules for cleavable signal se-ues were within 10% of the mean. HeLa cells (open circles) and
quences.CHO-K1 cells (closed circles), values obtained 4 hr after ONPG
addition. An epitope-tagged version of HVEM was also engi-
(B and C) CHO-K1 cells were transfected with control plasmid neered by fusing HVEM cDNA encoding the first 257
pcDNA3 (B) or with pBEC580, isolated from the human cDNA library amino acids (see Figure 2) to an oligonucleotide encod-
for its ability to confer susceptibility to HSV-1 infection (C). At 30 hr ing an influenza virus hemagglutinin epitope (Flu epi-
after transfection, the cells were exposed to KOS-gL86 at 100 pfu/
tope). CHO-K1 cells transfected with a plasmid ex-cell. Later (6 hr) the cells were washed, fixed, and incubated with
pressing this protein (HVEM-257Flu) produced severalX-gal to identify infected cells.
Flu-tagged HVEM species ranging in size from about 30
to 90 kDa (Figure 4B). The higher molecular mass spe-
Searches of protein databases with the predicted cies may be multimers of HVEM-257Flu or have bulky
HVEM amino acid sequence failed to identify any pro- posttranslational modifications.
teins closely related to HVEM but did identify cysteine- Rabbits were immunized with purified HVEM:Fc and
rich repeats in HVEM that are characteristic of the TNF/ antiserum tested for antibodies specific for HVEM. Cell
NGF receptor family (Armitage, 1994). Pair-wise align- extracts from CHO-K1 cells transfected with control or
ments of HVEM sequence with those of other human HVEM-257Flu-expressing plasmids were immunopre-
members of the receptor family revealed sequence iden- cipitated with rabbit antiserum or control preimmune
tities ranging from 16.9% to 25.4% and similarities rang- serum, followed by Western analyses for detection of the
ing from 26.9% to 37.1%. However, cysteines and other Flu epitope. The rabbit antiserum precipitated HVEM-
residues conserved within the cysteine-rich repeat re- 257Flu (lanes 1 and 2) but not a Flu-tagged HSV-1 gly-
gions of family members were also conserved in HVEM coprotein (lane 3), whereas preimmune serum lacked
(residues marked with asterisks in Figure 2). Clearly, specific precipitating activity (Figure 4C). Anti–HVEM
HVEM is a new member of the TNF/NGF receptor family. antibodies preferentially precipitated the higher molecu-
Southern analyses were performed with HVEM probes lar mass forms of HVEM-257Flu.
and genomic DNAs from various cell lines. Probes from
the purified cDNA hybridized to genomic DNA fragments HVEM–Mediated Entry of HSV-1 and HSV-2
from HeLa and HEp-2 (human) cells, Vero (monkey) cells, Strains into Transfected Cells
and CHO-HVEM12 cells (stably transfected with an CHO-K1 and ST cell lines, both resistant to HSV-1 entry,
HVEM cDNA clone), but not from control CHO-K1 cells were transfected with control or HVEM–expressing plas-
mids to obtain stable clones. The HVEM–expressing(Figure 3). The smaller PvuII probe hybridized to a single
TNF/NGF Receptor Family Member Mediates HSV Entry
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Figure 2. Nucleotide Sequence of the HVEM cDNA and Amino Acid Sequence of the Open Reading Frame
Features of the 283 amino acid open reading frame include a signal peptide (dotted underline), two potential sites for the addition of N-linked
carbohydrate (single underline), and the probable membrane-spanning domain (double underline). Also indicated by patterned bars under the
amino acid sequence are the three complete and one partial cysteine-rich repeats characteristic of members of the TNF/NGF receptor family.
Asterisks show the positions of amino acids that are highly conserved in the family. The arrow after Cys-185 indicates the last amino acid of
HVEM present in the fusion protein, HVEM:Fc. The arrow after Ala-257 indicates the last amino acid of HVEM present in the epitope-tagged
truncated protein, HVEM257-Flu. The sequence deposited in GenBank was assigned accession number U70321.
clones were 100–1000 times more susceptible to KOS- HVEM–expressing clones did not differ from control
clones or parental cell lines in susceptibility to infectiongL86 infection than control clones (Figure 5A), which
were as resistant as the parental cell lines. CHO-K1 by a b-galactosidase–expressing mutant of PRV (data
not shown). Thus, HVEM is not a general mediator ofcells, but not ST cells, are also resistant to entry of
a porcine alphaherpesvirus, pseudorabies virus (PRV). alphaherpesvirus entry.
Cell
430
Infection of HVEM–expressing cells (CHO-HVEM12
and ST-HVEM1) by KOS-gL86 was inhibited in a dose-
dependent manner by anti–HVEM serum or HVEM:Fc
but not by preimmune serum or normal rabbit IgG (Fig-
ures 5B and 5C). In fact, preimmune serum reproducibly
enhanced infection. As expected, neither anti–HVEM se-
rum nor HVEM:Fc inhibited PRV infection of ST-HVEM1
cells (data not shown).
To determine whether the anti–HVEM serum inhibited
HSV binding, CHO-HVEM12 cellswere exposed to radio-
labeled KOS at several virus concentrations to quanti-
tate virus binding at 48C in the presence of anti–HVEM
serum or preimmune serum at a 1:90 dilution. This dilu-
tion of antiserum completely inhibited HSV-1 infection
at all input doses of virus tested (Figure 5B; data not
shown) but did not inhibit virus binding (data not shown).
Thus, the antibodies blocked infection by interfering
with penetration (or possibly with events leading to un-
coating and expression of the genome). The antibodies
did not render the cells unresponsive to virus entry in
general or inhibit cell functions required for gene expres-
sion. Antibody-treated ST-HVEM1 cells remained fully
susceptible to PRV entry and expressed b-galactosi-
dase from the viral genome.
The ability of HVEM to mediate entry of other strains
of HSV was determined.CHO-IEb8 cells transfected with
HVEM–expressing or control plasmid were challenged
with various concentrations of different HSV-1 and
HSV-2 strains. These cells contain the Escherichia coli
lacZ gene downstream of an HSV-1 immediate-early
promoter and express b-galactosidase upon viral entry
and delivery of the HSV trans-inducer VP16 (Campbell
et al., 1984; Batterson and Roizman, 1983) into the cell.
Expression of HVEM significantly enhanced entry of all
wild-type HSV-1 and HSV-2 strains tested (Figure 6).
CHO-IEb8 cells transfected with control plasmid, like
parental CHO-K1 cells, did not completely resist entry
of HSV-1(MP) and HSV-2(333) (Figure 6). Some hamster
factor probably mediated their entry, albeit inefficiently.
HSV-2 strains in general infect CHO-K1 cells more effi-
ciently than do HSV-1 strains (Shieh et al., 1992). HSV-
1(MP) and HSV-1(KOS)804 are syncytial mutants with
enhanced ability to induce cell fusion due to missenseFigure 3. Southern and Northern Blots for Detection of HVEM–
mutations in gK (Pogue-Geile and Spear, 1987; Roop etHomologous DNA and RNA in Cells and Tissues
al., 1993). HSV-1(ANG) also has a syncytial phenotype(A–C) Cell DNAs were extracted and digested with BamHI and the
due to a missense mutation in gB (Weise et al., 1987).fragments separated by electrophoresis and transferred to Duralon
Thus, the syncytial phenotype does not explain the en-nylon membrane for hybridization. The DNAs were from HeLa (lanes
2), HEp-2 (lanes 3), CHO-K1 (lanes 4), CHO-HVEM12 (lanes 5), and hanced ability of HSV-1(MP) to infect CHO cells.
Vero (lanes 6) cells. BamHI-digested plasmid, pBEC580, was also Expression of HVEM failed to enhance the entry of
included (lanes 7). HSV-1(KOS)rid1 (KOS-rid1), HSV-1(KOS)rid 2 (KOS-rid2;
(A) Photograph of the ethidium bromide–stained gel.
data not shown), and HSV-1(ANG) (Figure 6). KOS-rid1(B) Autoradiogram of the blot using the PvuII probe indicated in (D).
and KOS-rid2 are mutants selected for resistance to gD-(C) Autoradiogram of the blot using the EcoRI probe indicated in (D).
mediated interference. Single amino acid substitutions(D) Schematic diagram of the HVEM cDNA and fragments used to
generate probes. Numbers on the left of (A) and bands in lane 1 in gD (Q27P or Q27R, respectively) account for theability
indicate molecular size markers (kbp). of these mutants to enter cells despite the block im-
(E) A Northern blot (Clontech) of polyadenylated RNAs extracted posed by expression of wild-type gD by the cells (Dean
from various human tissues and hybridized with a 32P-labeled probe
et al., 1994). HSV-1(ANG) has the same amino acid sub-from the PvuII fragment indicated in (D). The RNAs were extracted
stitution as KOS-rid2 (and other substitutions relative tofrom heart (lane 1), brain (lane 2), placenta (lane 3), lung (lane 4),
KOS gD) and is also resistant to gD-mediated interfer-liver (lane 5), skeletal muscle (lane 6), kidney (lane 7), and pancreas
(lane 8). Amounts on the blot were normalized with respect to actin ence (Dean et al., 1994). KOS-rid1 and KOS-rid2 are
mRNA content. somewhat impaired, compared with the parental strain
KOS, in ability to infect human Hep-2 cells, but they
infect HEp-2 cells much more efficiently than CHO-K1
TNF/NGF Receptor Family Member Mediates HSV Entry
431
Figure 4. Expression of the HVEM:Fc Hybrid
Protein and Epitope-Tagged HVEM-257Flu
and Immunoprecipitation of HVEM-257Flu
(A) Samples of purified HVEM:Fc were appro-
priately treated for incubation with Endo F,
Endo H, or Endo F/O-glycanase as indicated,
subjected to SDS–polyacrylamide gel elec-
trophoresis, and transferred to nitrocellulose
for Western blot analysis with anti-rabbit IgG
peroxidase conjugates and substrate for che-
miluminescent detection.
(B and C) CHO-K1 cells were transfected with
two different subclones of pBEC14 for ex-
pression of HVEM-257Flu (lanes 1 and 2), with pMN114 for expression of a Flu-tagged truncated version of HSV-1 gL (lane 3), or with
pcDNA3, a control plasmid (lane 4). At 48 hr after transfection, cell lysates were prepared and either immediately added to sample buffer for
SDS–polyacrylamide gel electrophoresis (B) or mixed with preimmune or immune rabbit serum for immunoprecipitation, followed by solubiliza-
tion of the immune precipitates for SDS–polyacrylamide gel electrophoresis (C). After electrophoresis, the separated proteins were transferred
to nitrocellulose for Western blotting with the anti-Flu MAb 12CA5. Asterisks indicate the multiple Flu-tagged forms of HVEM detected.
Numbers at the left of each panel indicate molecular mass markers in kDa.
cells (Dean et al., 1994). We conclude that viruses car- required for each entry event. Adenoviruses bind to cells
via fibers extending from vertices of the icosahedralrying the mutant (or ANG) form of gD cannot use HVEM
as a mediator of entry but enter human cells by other virions through as yet undefined interactions. Entry is
then facilitated by interaction of a protein at the basepathways.
HVEM–expressing CHO cells were permissive for viral of each fiber with cell-surface integrins (Wickham et al.,
1993). Human immunodeficiency virus binds to cells viareplication (data not shown), indicating that the principal
block to replication in CHO-K1 cells is at the stage of interaction of gp120 with CD4 (Dalgliesh et al., 1984;
Klatzmann et al., 1984; Maddon et al., 1988), but entryvirus entry. CHO-HVEM12 cells infected with KOS or
HSV-1(F) produced 10,000-fold or 100-fold more prog- requires cofactor activity which, for different virus
strains, can be provided by various members of theeny virus, respectively, than did control CHO-C8 cells
or CHO-K1 cells, but 10-fold to 100-fold less than did chemokine receptor family (Feng et al., 1996; Deng et
al., 1996; Dragic et al., 1996; Choe et al., 1996; DoranzHeLa cells.
et al., 1996; Alkhatib et al., 1996). Similarly, HSV binds to
cell-surface GAGs, but entry requires mediator activity,HVEM–Mediated Entry of HSV into Human Cells
which was shown here to be provided by HVEM. ItUse of the rabbit antiserum to detect HVEM on surfaces
should be noted that both GAGs and a mediator ofof human cells revealed that activated peripheral blood
entry such as HVEM are required for HSV infection. Cellsmononuclear cells expressed higher levels of HVEM
lacking GAGs (Shieh et al., 1992; Banfield et al., 1995)than cell lines such as 293 and HeLa (C. Ware, R. I. M.,
or a mediator can be 100–1000 times more resistant toand P. G. S., unpublished data). Phytohemagglutinin-
infection than cells expressing both.activated T cell blasts (greater than 95% CD31 and
The stage of HSV entry at which HVEM operates mustCD251) were prepared and shown to express HVEM
be either the membrane fusion reaction that occurs after(Figure 7A). These cells were exposed to viruses ex-
binding of virus to cell-surface GAGs or the release ofpressing wild-type gD (KOS-gL86) or a mutant form of
internal virion proteins, including VP16, from sites ofgD (HSV-1[KOS]rid1-tk12 [KOS-rid1-tk12], a b-galactos-
entry and their transport to the cell nucleus. This followsidase–expressing version of KOS-rid1) in the absence
from our findings that virus binding to CHO-K1 cellsor presence of anti–HVEM serum or preimmune serum.
occurs efficiently in the absence of HVEM or in the pres-In absence of either serum, the T cell blasts were more
ence of anti–HVEM antibody. Also, the ability of HVEMsusceptible to infection with KOS-gL86 than with KOS-
rid1-tk12 (Figure 7B). As was noted with the HVEM– to enhance HSV entry can be detected in CHO-IEb8
expressing CHO and ST cells, anti–HVEM serum had a cells, which carry a reporter gene under control of an
dose-dependent inhibitory effect on infection and pre- immediate-early HSV-1 promoter. In these cells, intro-
immune serum had a stimulatory effect, but only with duction of input viral VP16 into the cell nucleus suffices
KOS-gL86 (Figure 7B). Results similar to those shown to induce b-galactosidase expression and score an en-
in Figure 7 were obtained with activated T cell blasts try event.
from four different donors. We conclude that infection of It seems likely that HVEM interacts with one or more of
T cell blasts with KOS-gL86 is largely HVEM–dependent. the virion envelope glycoproteins to trigger membrane
fusion or induce postfusion uncoating events. The find-
ing that HVEM:Fc can inhibit HSV infection is consistentDiscussion
with direct interaction with virion surface proteins. Can-
didate proteins include the four envelope glycoproteinsDemonstration that a new member of the TNF/NGF re-
(gB, gD, gH, and gL) required for HSV-1 entry but notceptor family, HVEM, can mediate entry of HSV identifies
for binding of virus to cells. Functional interaction ofanother important family of cell-surface receptors used
virions with HVEM is influenced by gD because aminoby viruses for entry. This adds to the growing body of
evidence that multiple cell-surface components can be acid substitutions in gD eliminated ability of HSV-1 to
Cell
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Figure 6. Enhanced Entry of HSV-1 and HSV-2 Strains into HVEM–
Expressing CHO-IEb8 Cells
CHO-IEb8 cells were transfected with the HVEM–expressing plas-
mid pBEC10 (diagonally hatched bars) or the control plasmid
pcDNA3 (open bars). At 24 hr after transfection, the cells were re-
plated in 96 well dishes and, 24 hr later, exposed to various input
doses of each of the virus strains indicated. Later (6 hr), the cells
were lysed and ONPG added for the quantitation of viral entry. The
results presented are for a single input dose of virus (30,000 pfu
added per well) in the linear range of the dose response curve.
enter cells via HVEM (Figure 6) but not via other path-
ways of entry (Dean et al., 1994).
The role of HVEM in HSV entry could be completely
dissociable from its normal physiological role. Ligand
or ligands for HVEM and the consequences of ligand–
receptor interaction remain to be identified. There is no
obvious relationship between HSV envelope proteins
and members of the TNF/NGF ligand family, although
Figure 5. Enhanced Entry of HSV-1(KOS) into HVEM–Expressing virions need not interact with HVEM in the same manner
Cell Lines and Inhibition of Infection by Anti–HVEM Antibodies or as its natural ligand. For members of the TNF/NGF re-
HVEM:Fc
ceptor family, binding of ligand results in aggregation of
(A) Several HVEM–expressing and control cell lines were obtained
receptors and activation of specific signal transductionby transfection of CHO-K1 cells or ST cells with pBEC10 or control
pathways (Armitage, 1994; Heller and Kro¨nke, 1994;plasmid pcDNA3, followed by selection for stable maintenance of
Rothe et al., 1994). Binding of cognate receptors bythe plasmid. Representative clones were plated in 96 well plates
and exposed to KOS-gL86 at the doses indicated. Later (6 hr), viral members of the TNF or NGF family can have a variety
entry was quantitated as described in the legend to Figure 1. CHO- of effects, including induction of cell proliferation, differ-
HVEM11 and ST-HVEM1 (open circles), CHO-HVEM9 and ST- entiation, or apoptosis, depending on the particular re-
HVEM22 (closed circles), and CHO-HVEM12 and ST-HVEM2 (open ceptor, ligand, and other factors (Smith et al., 1994;
squares) were isolated after transfection with the HVEM–expressing
Rabizadeh and Bredesen, 1994; Maness et al., 1994).plasmid pBEC10.CHO-C8 and ST-C8(closed squares)were isolated
Interestingly, another human herpesvirus, Epstein-Barrafter transfection with the control plasmid pcDNA3.
virus, expresses a membrane protein that interacts(B and C) CHO-HVEM12 cells or ST-HVEM1 cells were plated in 96
well dishes. In (B), the cells were exposed to preimmune or immune through a cytoplasmic domain with cytoplasmic pro-
rabbit serum at the dilutions indicated for 30 min at 378C. Various teins responsible for transmitting signals usually initi-
amounts of KOS-gL86 were then added in one-fifth volume, and ated by ligand binding to a TNF receptor family member
incubation continued for 2 hr. In (C), virus was mixed with various (Mosialos et al., 1995). If any aspect of signaling through
concentrations of HVEM:Fc or normal rabbit IgG and incubated for
HVEM requires the C-terminal 26 amino acids, we can30 min at 378C. The mixtures (50 ml) were added to washed cells, and
rule out its requirement for HSV entry based on theincubation continued for 2 hr. The virus–serum or virus–HVEM:Fc
ability of HVEM-257Flu tomediate infection of CHO cellsmixtures were then removed and the cells exposed briefly to low
pH buffer to inactivate residual extracellular virus. The cells were (data not shown).
washed and incubatedfor an additional 4 hr before lysis and addition Several lines of evidence indicate that othermediators
of ONPG. The amount of virus added was 107 pfu/well in (B) and of HSV entry have yet to be identified. First, although
106 pfu/well in (C). Open symbols were preimmune serum (B) or the cDNA for HVEM was isolated from a HeLa cell library,
normal rabbit IgG (C). Closed symbols were immune serum (B) or
HVEM is probably not the principal mediator of HSVHVEM:Fc (C).
entry into HeLa cells. The anti–HVEM serum and
HVEM:Fc had only marginal ability to block HSV-1 infec-
tion of HeLa cells (data not shown). Second, strains
TNF/NGF Receptor Family Member Mediates HSV Entry
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its expression in resistant cells did not enhance suscep-
tibility to HSV entry (Shieh and Spear, 1991; Mirda et
al., 1992). Mannose-6-phosphate receptors have also
been proposed to mediate entry of HSV-1, but cell mu-
tants lacking these receptors remain fully susceptible
to viral entry (Brunetti et al., 1995). The effect of expres-
sion of these receptors in cells resistant to infection
needs to be explored.
The fact that HVEM enhances entry of the wild-type
HSV-1 and HSV-2 strains tested and mediates HSV entry
into activated T cells highlights its probable importance
in HSV pathogenesis. Several reports have described
the replication of HSV in activated T cells (Pelton et al.,
1977; Rinaldo et al., 1978; Teute et al., 1983) and the
presence of infected lymphocytes in biopsies of cutane-
ous lesions (Boddingius et al., 1987). Because HVEM is
a principal mediator of HSV entry into activated T cells,
and subtle genetic alterations in HSV can eliminate abil-
ity to utilize HVEM as an entry mediator, virus strains in
the field may differ in ability to infect activated T cells.
The virulence of a virus strain is influenced by its ability
to infect lymphocytes, whether this infection promotes
virus spread or abrogates localized immune responses.
Discovery of HVEM opens new areas of investigation,
including exploration of factors that induce HVEM ex-
pression in lymphocytes and other human cells, po-
tential role of signal transduction in viral entry or viral
replication, and effects of human or viral genetic poly-
morphisms on HVEM–virus interactions.
Experimental Procedures
Cells and Viruses
CHO-K1, HEp-2, HeLa, Vero, and ST cells were obtained from the
American Type Culture Collection and HT1080 cells from Dr. N.
Bouck (Northwestern University). The CHO-IEb8 cell line was iso-
lated after transfection of CHO-K1 cells with pMLP01, a plasmid
having the E. coli lacZ gene under control of the HSV-1 ICP4 pro-
moter and expressing b-galactosidase upon infection of cells withFigure 7. Expression of HVEM on Human T Lymphoblasts and
HSV (M. L. Parish, R. I. M., and P. G. S., unpublished data).HVEM–Dependent Infection by HSV-1 Expressing Wild-Type gD
Wild-type virus strains used were HSV-1(KOS), HSV-1(HFEM),
(A) Activated T cells were incubated with anti–HVEM antiserum HSV-1(Patton), HSV-1(F) (Ejercito et al., 1968), HSV-1(SC16), HSV-
(shaded profile) or preimmune serum (open profile), followed by a 1(17) (McGeoch et al., 1988), and HSV-2(333). Mutant strains in-
fluoresceinated second antibody, and analyzed by flow cytometry. cluded KOS-rid1 and rid2 (Dean et al., 1994), HSV-1(KOS)804 (Little
(B) Activated T cells were infected with KOS-gL86 or KOS-rid1-tk12 and Schaffer, 1981), HSV-1(MP) (Hoggan and Roizman, 1959), and
(107 pfu/well) in the absence or presence of anti–HVEM antiserum HSV-1(ANG) (Munk and Donner, 1963; Weise et al., 1987; Dean et
or preimmune serum. The cells were lysed and b-galactosidase al., 1994). KOS-rid1-tk12 is a recombinant virus produced by in-
activity quantitated at 6 hr after infection. The inset presents serting the E. coli lacZ gene driven by the HSV-1 ICP4 promoter in
b-galactosidase activity expressed by KOS-gL86 (circles) or KOS- place of the thymidine kinase gene of KOS-rid1. These strains were
rid1-tk12 (squares) with preimmune (open symbols) or immune propagated by passage on HEp-2 cells and titered on Vero cells.
(closed symbols) serum. The large panel presents b-galactosidase KOS-gL86, a mutant in which the E. coli lacZ gene with CMV pro-
in anti–HVEM–treated samples as a percentage of control values moter replaces part of the gL open reading frame (M. J. Novotny
obtained with an equivalent concentration of preimmune serum, for and P. G. S., unpublished data), was propagated and titered on gL-
KOS-gL86 (closed circles) and KOS-rid1-tk12 (open squares). expressing Vero cell transfectants. A PRV mutant, in which the gH
gene was interrupted by the lacZ gene (Klupp et al., 1994), was
obtained from T. C. Mettenleiter and propagated and titered on gH-KOS-rid1, rid2, and HSV-1(ANG) can infect various hu-
expressing Vero cell transfectants. Mutant viruses obtained from
man cell types but fail to infect HVEM–expressing CHO- these complementing cell lines were fully infectious for and ex-
K1 cells. Third, CHO-K1 cells express some factor that pressed b-galactosidase in noncomplementing cells but produced
can mediate the entry of certain HSV strains, especially only noninfectious virus.
HSV-2 strains. Finally, continued screening of the HeLa
Infectivity Assayscell cDNA library with other strains of HSV-1 indicates
Infectivity assays were based on quantitation of b-galactosidasethe presence of other genes that can mediate HSV entry
expressed from the viral genome or by the b-galactosidase–(M. S. Warner, R. J. Geraghty, R. I. M., and P. G. S.,
expressing cell line CHO-IEb8. Adherent cells were plated in 96 well
unpublished data). These genes are not likely to encode tissue culture dishes (2–4 3 104 cells/well) at least 16 hr prior to
basic fibroblast growth factor receptor, previously pro- infection. Cells were washed and exposed to virus (in 50 ml of phos-
phate-buffered saline [PBS] containing glucose and 1% calf serumposed tomediate HSV entry (Kaner et al., 1990), because
Cell
434
[PBS-G-CS]) for 6 hr at 378C before solubilization in 100 ml of PBS Southern and Northern Blots
Genomic DNAs were isolated (Hirt, 1967), digested with BamHI, andcontaining 0.5% NP-40 and the b-galactosidase substrate, o-nitro-
phenyl b-D-glucopyranoside (ONPG, 3 mg/ml). The reaction was electrophoresed on 0.8% agarose gels. Southerns were performed
by standard procedures. Briefly, DNA was transferred to Duralonmonitored by spectrometry at several timepoints after the addition
of ONPG to define the interval over which the generation of product nylon membrane. Randomly primed probes were generated using
digoxigen-labeled nucleotides (Genius Kit; Boehringer Mannheim)was linear with time (Dynatech ELISA reader or a Spectromax 250).
Alternatively, cells plated in 6 well tissue-culture dishes were ex- or 32P-labeled nucleotides. Prehybridization was for 2 hr in hybridiza-
tion buffer with Denhardt’s reagent and 50% formamide. After hy-posed to virus and infected cells visualized using the b-galactosi-
dase substrate X-gal (GIBCO Laboratories), which yields an insolu- bridization with probe at 428C for 24 hr, membranes were incubated
twice for 15 min at 658C with 0.2 3 SSC containing 0.1% SDS. Theble blue reaction product. After infection, washed cells were fixed
(PBS containing 2% formaldehyde and 0.2% gluteraldehyde), per- blot was exposed to X-ray film at 2708C (for 32P-labeled probes) or
processed for digoxigen detection by chemiluminescence (Boeh-meabilized (2 mM MgCl2 containing 0.01% deoxycholate and 0.02%
NP-40), and incubated with buffered X-gal (0.5 mg/ml). Antibody ringer Mannheim), utilizing the alkaline phosphatase substrate CDP-
STARTM (Tropix).inhibition assays were performed as described for infectivity assays
in 96 well plates, except that rabbit serum diluted in PBS-G-CS was Northern analysis was performed using a commercial blot of poly-
adenylated RNAs extracted from various human tissues (Clontech).added to the cells (50 ml/well) 30 min before addition of virus (10
ml/well). After 2 hr with the serum–virus mixtures, the cells were Prehybridization and hybridization of the blot were done as de-
scribed above at 428C and washes with 0.2 3 SSC containing 0.1%treated with 0.1 M citrate buffer (pH 3.0) for 1 min to inactivate
extracellular virus (Huang and Wagner, 1964; Highlander et al., 1987). SDS were at 508C. The blot was exposed to X-ray film at 2708C.
The cells were then washed and incubated in PBS-G-CS for 4 hr
before solubilization and quantitation of b-galactosidase activity. Plasmids and Stably Transfected Cell Lines
Assays for inhibition of infection by HVEM:Fc were similar, except Plasmid pBEC10, carrying the HVEM insert and a neomycin-resis-
that dilutions of virus were mixed with HVEM:Fc or rabbit IgG and tance gene, was generated by cloning a HindIII–XhoI fragment of
incubated for 30 min at 378C prior to addition of the mixtures (50 pBEC580 into pcDNA3. pBEC14, expressing HVEM-257Flu, was
ml/well) to washed cell monolayers. generated in several steps. The HindIII-to-SfiI fragment of the HVEM
Peripheral blood mononuclear cells were isolated by Ficoll- insert from pBEC580 was modified by deletion between the BamHI
Hypaque density gradient centrifugation of freshly collected hepa- and BstYI sites, then inserted between HindIII and EcoRI sites of
rinized blood and incubated 3 days at 106 cells/ml in RPMI-1640 pMN104 (blunt-end ligation between the SfiI and EcoRI sites after
containing 10% fetal bovine serum and purified phytohemagglutin Klenow treatment). pMN104 contains an oligonucleotide, inserted
(Sigma Chemicals) at 5 mg/ml. T cell blasts were isolated on 50% between the EcoRI and XbaI sites of pcDNA3, that encodes 11
Percoll cushions and were routinely more than 95% CD31 and more amino acids (EFYPYDVPDYASL) plus a stop codon, including a 9
than 98% CD251. HVEM expression was determined by incubating amino acid Flu epitope (underlined, Wilson et al., 1984). pMN114,
cells with the anti–HVEM rabbit serum or preimmune serum, fol- also derived from pMN104, expresses a truncated Flu-tagged ver-
lowed by goat anti-rabbit fluoresceinated secondary antibodies and sion of HSV-1 gL (M. J. Novotny and P. G. S., unpublished data).
flow cytometry (Beckton-Dickenson FACScan). Remaining cells pBL58, expressing a hybrid form of HVEM (the ectodomain fused
were dispensed into 96 well plates (105 cells/well) for infectivity to the hinge, CH2 and CH3 domains of the rabbit IgG heavy chain),
studies. Assays were as described above except that after 2 hr of was generated in several steps. It consists of a cytomegalovirus
incubation, the virus inocula were removed and replaced with me- promoter from pcDNAneo (SpeI to HindIII); HindIII to XbaI from
dium containing preimmune or immune serum at the same concen- pGEM3; the ectodomain of HVEM from pBEC580 (NheI site to a
trations as present during virus inoculation. PvuII site just downstream of the last Cys residue); a fragment of
The binding of virus to cells was quantitated as described pre- rabbit IgG heavy chain cDNA from plasmid 3-4 (obtained from K.
viously (Shieh et al., 1992) using 3H-thymidine-labeled purified HSV- Knight at Loyola University Medical Center) including an EcoRI site
1(KOS). added by polymerase chain reaction 59 to the rabbit sequence
ACAAGACCGTTGC and extending to a PstI site downstream of the
reading frame (after cleavage with EcoRI, the filled-in site was bluntIsolation and Sequencing of the HVEM cDNA
end–ligated to the PvuII end of the HVEM fragment); and HindIII toA unidirectional HeLa cell cDNA expression library cloned into
NheI from pGEM4 (the PstI end of the rabbit sequence was bluntpcDNA1 in E. coli (InVitrogen) was plated onto 100 150 mm Luria-
end–ligated to the HindIII site, and the NheI site was ligated to theBertani plates containing appropriate drugs (1.5 3 105 bacteria/
SpeI site of the CMV promoter fragment).plate). Colonies were pooled by scraping and frozen as 100 glycerol
Stable HVEM–expressing cell lines were produced by transfectionstocks. Samples of each stock were combined into groups of 10
of CHO-K1 cells and ST cells with pBEC10 and selection in mediumand grown to stationary phase in broth. Plasmids prepared from
containing Geneticin (500 mg/ml for CHO-K1 cells and 800 mg/mleach culture were transfected into CHO-K1 cells using LipofectAM-
for ST cells). Surviving cells were cloned by limiting dilution, andINE (GIBCO Laboratories; 1.5 mg of plasmid and 5 ml of LipofectAM-
cell clones susceptible to KOS-gL86 infection were subcloned andINE/35 mmculture). For controls, cellswere transfected with pMN84,
expanded. Control cell lines were produced by transfecting CHO-K1a plasmid expressing b-galactosidase, or were incubated with Lipo-
and ST cells with pcDNA3 and isolating Geneticin-resistant clones.fectAMINE alone. At 30 hr after transfection, the cells were washed,
inoculated with KOS-gL86 at about100 pfu percell, and then stained
with X-gal as described above. Transfection efficiencies ranged HVEM:Fc Production, Characterization, and Use
as Immunogenfrom 30%–55% of cells based on expression of b-galactosidase
from pMN84 in uninfected cells. In the first round of screening the HVEM:Fc secreted into the medium of pBL58-transfected CHO-K1
cells was purified by Protein G–Sepharose chromatography.cDNA library, plasmids from one group of 10 bacterial stocks from
the library converted about 20–30 cells in the monolayer to suscepti- HVEM:Fc was denatured by boiling for 5 min in 0.5% SDS, 1%
b-mercaptoethanol, and carbohydrate modifications determined bybility to KOS-gL86 infection. The frequency of conversion to suscep-
tibility was about 10 times higher for one of the 10 stocks in this incubating overnight at 378C with endo F (200 mU, 1% NP-40, 50
mM sodium phosphate [pH 7.5]) or endo H (1 mU, 50 mM sodiumgroup. This stock was divided again into 100 pools, and, by an
iterative process, two bacterial clones were obtained that yielded citrate [pH 5.5]) or without added enzyme (1% NP-40,50 mM sodium
phosphate [pH 7.5]). Alternatively, samples were digested overnightplasmids (pBEC580 and pBEC748) with the desired phenotype.
Both strands of the cDNA insert of pBEC580 were sequenced at 378C with neuraminidase (4 mU, 50 mM sodium citrate [pH 4.5]),
then denatured and incubated overnight at 378C with endo F (200using Sequenase (Amersham) and T7 and Sp6 primers, as well as
other primers generatedas sequence was obtained. All primers were mU) and O-glycosidase (0.5 mU) in 1% NP-40, 50 mM sodium phos-
phate (pH 7.5). Western blots of control and glycosidase-treatedobtained from the Northwestern University Biotechnology Center.
Single-strand sequencing of pBEC748 revealed the insert to be the samples were probed with a mixture of anti-rabbit IgG peroxidase
conjugates (GibcoBRL 9814SA and Sigma A6667) at concentrationssame as that of pBEC580.
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of 1:1000 in BLOTTO (10 mM Tris [pH 7.4], 150 mM NaCl, 5% pow- Campbell, M.E.M., Palfreyman, J.W., and Preston, C.M. (1984). Iden-
tification of herpes simplex virus DNA sequences which encode adered milk, 0.05% Tween-20), followed by chemiluminescent detec-
tion with ECL reagent and Hyperfilm-MP (Amersham). trans-acting polypeptide responsible for stimulation of immediate
early transcription. J. Mol. Biol. 180, 1–19.Rabbit polyclonal antibodies were produced by subcutaneous
injection of purified HVEM:Fc mixed with Hunter’s TiterMax adjuvant Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P.D.,
at Pocono Farms, Inc. For immunoprecipitation, lysates were pre- Wu, L., Mackay, C.R., LaRosa, G., Newman, W., Gerard, N., Gerard,
pared with 1% Triton X-100 in 150 mM NaCl, 20 mM Tris–HCl (pH C., and Sodroski, J. (1996). The b-chemokine receptors CCR3 and
8.0), containing protease inhibitors (2 mg/ml of aprotinin; 2 mg/ml of CCR5 facilitate infection by primary HIV-1 isolates. Cell 85, 1135–
leupeptin; 1 mg/ml of pepstatin A; 5 mM phenylmethylsulfonyl fluo- 1148.
ride) and mixed on ice with rabbit preimmune or immune serum (10 Corey, L., and Spear, P.G. (1988). Infections with herpes simplex
ml/200 ml of lysate). Samples of cell lysates and immunoprecipitates viruses. N. Engl. J. Med. 314, 686–689; 749–757.
collected on Protein A–agarose were subjected to SDS–poly-
Dalgliesh, A.G., Beverley, P.C.L., Clapham, P.R., Crawford, D.H.,acrylamide gel electrophoresis and transferred to nitrocellulose
Greaves, M.F., and Weiss, R.A. (1984). The CD4 (T4) antigen is anmembranes. The membranes were incubated in BLOTTO for 1 hr
essential component of the receptor for the AIDS retrovirus. Natureof blocking and then with the anti-hemagglutinin antibody 12CA5
312, 763–766.(Wilson et al., 1984) diluted1:5000 in BLOTTO, followed by horserad-
Dean, H.J., Terhune, S., Shieh, M.-T., Susmarski, N., and Spear, P.G.ish peroxidase–coupled goat anti-mouse IgG (Boehringer Mann-
(1994). Single amino acid substitutions in gD of herpes simplexheim) diluted1:10,000. Detection of second antibody was by incuba-
virus 1 confer resistance to gD-mediated interference and causetion in ECL reagent and exposure to Amersham Hyperfilm-MP
cell type–dependent alterations in infectivity. Virology 199, 67–80.(Amersham).
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